中国生物科技服务(08037.HK)附属以发行代价股份方式收购中国精准医学科技控股70%股份
格隆汇8月13日丨中国生物科技服务(08037.HK)公布，于8月12日，公司及买方Grande Fortune International Limited(公司一间直接全资附属公司)与该等卖方伟达高投资有限公司及杨晓楠、目标公司中国精准医学科技控股有限公司、营运公司深圳中科普瑞生物技术有限公司、共青城普瑞、李伟波、李友谊及伍世江订立买卖协议，据此，买方购买而该等卖方出售待售股份，代价为人民币7000万元。代价将以发行代价股份方式支付。
公告显示，每股代价股份发行价2港元，较收市价每股1.38港元溢价约44.9%，向第一卖方伟达高投资有限公司发行及配发3035.85万股股份及向第二卖方杨晓楠发行及配发849.15万股股份。
代价股份于发行后，将合共占公司于公告日期现有已发行股本约4.01%，占公司经发行代价股份而扩大后已发行股本约3.86%，以及占公司经发行代价股份及富石收购事项代价股份而扩大后已发行股本约3.85%。
据悉，目标公司为一间投资控股公司，持有中国精准(HK)全部已发行股本，而中国精准(HK)则持有中国精准(WFOE)全部注册资本。作为其中一项条件，中国精准(WFOE)将于完成前与营运公司及营运公司新登记股东订立新可变利益实体合约以取代现有可变利益实体合约，并将对营运公司集团财务及营运具有实际控制权，以及将透过新可变利益实体合约享有营运公司集团经济权益及利益。
根据买卖协议，目标公司将于完成日期与第二卖方订立认购选择权协议，向第二卖方授予认购选择权，在达到目标集团若干绩效目标之前提下，可分三批认购目标公司新股份，每批按全面摊薄基准占5%股权。第二卖方毋须就认购选择权支付任何权利金。于完成后，假设认购选择权获全数行使，则集团于目标公司权益将由70.0%被摊薄至约60.0%。
董事会认为，通过收购事项，将能够整合集团肿瘤基因检测及CAR-T肿瘤免疫治疗，进一步打造肿瘤诊疗一体化的业务步局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
